ACM
RAPP

Aster Capital Management’s Rapport Therapeutics RAPP Stock Holding History

Aster Capital Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300
Closed -$9.1K – 1413
2025
Q4 		$9.1K Buy
+300
New +$8.3K ﹤0.01% 760
2025
Q1 		– Sell
-5
Closed -$89 – 1735
2024
Q4 		$89 Buy
+5
New +$111 ﹤0.01% 1072

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Aster Capital Management's RAPP Position: Q1 2026 in Review

Aster Capital Management sold out of Rapport Therapeutics (RAPP) in Q1 2026, closing a stake of 300 shares — an estimated $9.1K sold.

Aster Capital Management first reported a position in RAPP in Q4 2024 and held it in 2 quarters. The position peaked at $9.1K in Q4 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Aster Capital Management reported no remaining Rapport Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aster Capital Management sold 300 Rapport Therapeutics shares in Q1 2026, an estimated $9.1K.
  • Aster Capital Management first reported a position in Rapport Therapeutics in Q4 2024 and held it in 2 quarters.
  • Aster Capital Management's Rapport Therapeutics position peaked at $9.1K in Q4 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.